{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:52:37Z","timestamp":1740163957709,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We systematically analyzed the kinetics of tumor regression, the impact of residual lesions on disease control and the applicability of the Lugano classification in follow-up MRI of orbital non-Hodgkin lymphomas that were irradiated with photons. We retrospectively analyzed a total of 154 pre- and post-irradiation MRI datasets of 36 patients with low-grade, Ann-Arbor stage I, orbital non-Hodgkin lymphomas. Patients with restricted conjunctival involvement were excluded. Lymphoma lesions were delineated and volumetrically analyzed on T1-weighted sequences. Tumor residues were present in 91.2% of all cases during the first six months after treatment. Volumetric partial response rates (&gt;\u200950% volume reduction) were 75%, 69.2%, and 50% at 12\u201324\u00a0months, 36\u201348\u00a0months and &gt;\u200948\u00a0months after the end of treatment. The corresponding complete response (CR) rates according to the Lugano classification were 20%, 23.1% and 50%. During a median clinical follow-up of 37\u00a0months no significant differences in progression free survival (PFS) rates were observed between the CR and non-CR group (<jats:italic>p<\/jats:italic>\u2009=\u20090.915). A residual tumor volume below 20% of the pretreatment volume should be expected at long-term follow-up beyond one year after radiotherapy.<\/jats:p>","DOI":"10.1038\/s41598-023-31941-w","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T14:03:16Z","timestamp":1679580196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy: imaging remission criteria and volumetric regression kinetics"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-439X","authenticated-orcid":false,"given":"Christian","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Huettmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"G\u00f6ricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelius","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Poettgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gauler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nika","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sourour","family":"Moliavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Bechrakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"31941_CR1","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/s0360-3016(03)00767-3","volume":"57","author":"CY Fung","year":"2003","unstructured":"Fung, C. Y. et al. Ocular adnexal lymphoma: Clinical behavior of distinct World Health Organization classification subtypes. Int. J. Radiat. Oncol. Biol. Phys. 57, 1382\u20131391. https:\/\/doi.org\/10.1016\/s0360-3016(03)00767-3 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"31941_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","volume":"92","author":"J Yahalom","year":"2015","unstructured":"Yahalom, J. et al. Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int. J. Radiat. Oncol. Biol. Phys. 92, 11\u201331. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.009 (2015).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"31941_CR3","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3109\/10428194.2014.979415","volume":"56","author":"RR Parikh","year":"2015","unstructured":"Parikh, R. R. et al. Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy. Leuk. Lymphoma 56, 1266\u20131270. https:\/\/doi.org\/10.3109\/10428194.2014.979415 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"31941_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2141.2010.08429.x","volume":"152","author":"S Bayraktar","year":"2011","unstructured":"Bayraktar, S., Bayraktar, U. D., Stefanovic, A. & Lossos, I. S. Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): Single institution experience in a large cohort of patients. Br. J. Haematol. 152, 72\u201380. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08429.x (2011).","journal-title":"Br. J. Haematol."},{"key":"31941_CR5","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.21873\/anticanres.14400","volume":"40","author":"S Rehn","year":"2020","unstructured":"Rehn, S. et al. Radiotherapy dose and volume de-escalation in ocular adnexal lymphoma. Anticancer Res. 40, 4041\u20134046. https:\/\/doi.org\/10.21873\/anticanres.14400 (2020).","journal-title":"Anticancer Res."},{"key":"31941_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ijrobp.2010.07.1992","volume":"81","author":"M Hata","year":"2011","unstructured":"Hata, M. et al. Treatment effects and sequelae of radiation therapy for orbital mucosa-associated lymphoid tissue lymphoma. Int. J. Radiat. Oncol. Biol. Phys. 81, 1387\u20131393. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.07.1992 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"31941_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.radonc.2008.09.011","volume":"90","author":"H Nam","year":"2009","unstructured":"Nam, H., Ahn, Y. C., Kim, Y. D., Ko, Y. & Kim, W. S. Prognostic significance of anatomic subsites: Results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma. Radiother. Oncol. 90, 236\u2013241. https:\/\/doi.org\/10.1016\/j.radonc.2008.09.011 (2009).","journal-title":"Radiother. Oncol."},{"key":"31941_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000453615","volume":"3","author":"S Platt","year":"2017","unstructured":"Platt, S. et al. Extranodal marginal zone lymphoma of ocular adnexa: Outcomes following radiation therapy. Ocul. Oncol. Pathol. 3, 181\u2013187. https:\/\/doi.org\/10.1159\/000453615 (2017).","journal-title":"Ocul. Oncol. Pathol."},{"key":"31941_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ijrobp.2013.11.235","volume":"88","author":"K Harada","year":"2014","unstructured":"Harada, K. et al. Localized ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiation therapy: A long-term outcome in 86 patients with 104 treated eyes. Int. J. Radiat. Oncol. Biol. Phys. 88, 650\u2013654. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.11.235 (2014).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"31941_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ajo.2018.11.002","volume":"199","author":"TG Olsen","year":"2019","unstructured":"Olsen, T. G. et al. Orbital lymphoma\u2014An International Multicenter Retrospective Study. Am. J. Ophthalmol. 199, 44\u201357. https:\/\/doi.org\/10.1016\/j.ajo.2018.11.002 (2019).","journal-title":"Am. J. Ophthalmol."},{"key":"31941_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J. Clin. Oncol. 32, 3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800 (2014).","journal-title":"J. Clin. Oncol."},{"key":"31941_CR12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/blood-2016-05-714584","volume":"129","author":"A Desai","year":"2017","unstructured":"Desai, A. et al. Long-term course of patients with primary ocular adnexal MALT lymphoma: A large single-institution cohort study. Blood 129, 324\u2013332. https:\/\/doi.org\/10.1182\/blood-2016-05-714584 (2017).","journal-title":"Blood"},{"key":"31941_CR13","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaophthalmol.2014.376","volume":"132","author":"PK Rasmussen","year":"2014","unstructured":"Rasmussen, P. K. et al. Ocular adnexal follicular lymphoma: A multicenter international study. JAMA Ophthalmol. 132, 851\u2013858. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.376 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"31941_CR14","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/j.ijrobp.2011.03.050","volume":"81","author":"JS Goda","year":"2011","unstructured":"Goda, J. S. et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: Efficacy and toxicity. Int. J. Radiat. Oncol. Biol. Phys. 81, e659-666. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.03.050 (2011).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"31941_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijrobp.2005.11.035","volume":"65","author":"CO Suh","year":"2006","unstructured":"Suh, C. O. et al. Orbital marginal zone B-cell lymphoma of MALT: Radiotherapy results and clinical behavior. Int. J. Radiat. Oncol. Biol. Phys. 65, 228\u2013233. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.11.035 (2006).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"31941_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eclinm.2018.10.001","volume":"4\u20135","author":"YW Jeon","year":"2018","unstructured":"Jeon, Y. W. et al. Comparison of selection and long-term clinical outcomes between chemotherapy and radiotherapy as primary therapeutic modality for ocular adnexal MALT lymphoma. EClinicalMedicine 4\u20135, 32\u201342. https:\/\/doi.org\/10.1016\/j.eclinm.2018.10.001 (2018).","journal-title":"EClinicalMedicine"},{"key":"31941_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cncr.11539","volume":"98","author":"T Uno","year":"2003","unstructured":"Uno, T. et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: A multiinstitutional, retrospective review of 50 patients. Cancer 98, 865\u2013871. https:\/\/doi.org\/10.1002\/cncr.11539 (2003).","journal-title":"Cancer"},{"key":"31941_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijrobp.2009.04.018","volume":"77","author":"SH Son","year":"2010","unstructured":"Son, S. H. et al. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma). Int. J. Radiat. Oncol. Biol. Phys. 77, 86\u201391. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.04.018 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"31941_CR19","first-page":"5575","volume":"33","author":"S Ohga","year":"2013","unstructured":"Ohga, S. et al. Radiotherapy for early-stage primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. Anticancer Res. 33, 5575\u20135578 (2013).","journal-title":"Anticancer Res."},{"key":"31941_CR20","doi-asserted-by":"publisher","first-page":"20210635","DOI":"10.1259\/bjr.20210635","volume":"95","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. The role of (18)F-FDG PET\/CT in diagnosis and treatment evaluation for ocular adnexal mucosa-associated lymphoid tissue lymphoma. Br. J. Radiol. 95, 20210635. https:\/\/doi.org\/10.1259\/bjr.20210635 (2022).","journal-title":"Br. J. Radiol."},{"key":"31941_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3053","author":"C Hoffmann","year":"2022","unstructured":"Hoffmann, C. et al. Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: Results from a longitudinal study. Hematol. Oncol. https:\/\/doi.org\/10.1002\/hon.3053 (2022).","journal-title":"Hematol. Oncol."},{"key":"31941_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0167-8140(00)00328-5","volume":"59","author":"SL Stafford","year":"2001","unstructured":"Stafford, S. L. et al. Orbital lymphoma: Radiotherapy outcome and complications. Radiother. Oncol. 59, 139\u2013144. https:\/\/doi.org\/10.1016\/s0167-8140(00)00328-5 (2001).","journal-title":"Radiother. Oncol."},{"key":"31941_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","volume":"15","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin, P. J. et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial. Lancet Oncol. 15, 457\u2013463. https:\/\/doi.org\/10.1016\/S1470-2045(14)70036-1 (2014).","journal-title":"Lancet Oncol."},{"key":"31941_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211035622","author":"MJ Lee","year":"2021","unstructured":"Lee, M. J., Lee, M. Y., Choe, J. Y., Choi, S. H. & Kim, H. J. Ultra-low-dose radiation treatment for early-stage ocular adnexal MALT lymphoma. Eur. J. Ophthalmol. https:\/\/doi.org\/10.1177\/11206721211035622 (2021).","journal-title":"Eur. J. Ophthalmol."},{"key":"31941_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry, L. et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. Radiother. Oncol. 100, 86\u201392. https:\/\/doi.org\/10.1016\/j.radonc.2011.05.013 (2011).","journal-title":"Radiother. Oncol."},{"key":"31941_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/ajco.13221","volume":"15","author":"J Lee","year":"2019","unstructured":"Lee, J. et al. Patterns of care for orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in Korea throughout 2016: Results from a multicenter cross-sectional cohort study (KROG 16\u201319). Asia Pac. J. Clin. Oncol. 15, 358\u2013363. https:\/\/doi.org\/10.1111\/ajco.13221 (2019).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"31941_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1148\/radiol.10100086","volume":"256","author":"LS Politi","year":"2010","unstructured":"Politi, L. S. et al. Ocular adnexal lymphoma: Diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring. Radiology 256, 565\u2013574. https:\/\/doi.org\/10.1148\/radiol.10100086 (2010).","journal-title":"Radiology"},{"key":"31941_CR28","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00277-015-2339-6","volume":"94","author":"SK Jung","year":"2015","unstructured":"Jung, S. K. et al. Suggestion of response evaluation criteria in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML). Ann. Hematol. 94, 1185\u20131193. https:\/\/doi.org\/10.1007\/s00277-015-2339-6 (2015).","journal-title":"Ann. Hematol."},{"key":"31941_CR29","doi-asserted-by":"publisher","first-page":"8925","DOI":"10.1007\/s00330-021-08026-1","volume":"31","author":"S Spijkers","year":"2021","unstructured":"Spijkers, S. et al. Whole-body MRI versus an [(18)F]FDG-PET\/CT-based reference standard for early response assessment and restaging of paediatric Hodgkin\u2019s lymphoma: A prospective multicentre study. Eur. Radiol. 31, 8925\u20138936. https:\/\/doi.org\/10.1007\/s00330-021-08026-1 (2021).","journal-title":"Eur. Radiol."},{"key":"31941_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s00330-018-5445-8","volume":"29","author":"A Latifoltojar","year":"2019","unstructured":"Latifoltojar, A. et al. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin\u2019s lymphoma: A comparison with multi-modality reference standard including (18)F-FDG-PET-CT. Eur. Radiol. 29, 202\u2013212. https:\/\/doi.org\/10.1007\/s00330-018-5445-8 (2019).","journal-title":"Eur. Radiol."},{"key":"31941_CR31","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/jmri.24938","volume":"42","author":"AS Littooij","year":"2015","unstructured":"Littooij, A. S. et al. Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study. J. Magn. Reson. Imaging 42, 1646\u20131655. https:\/\/doi.org\/10.1002\/jmri.24938 (2015).","journal-title":"J. Magn. Reson. Imaging"},{"key":"31941_CR32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/1097-0142(19870801)60:3<407::aid-cncr2820600321>3.0.co;2-n","volume":"60","author":"JL Chen","year":"1987","unstructured":"Chen, J. L., Osborne, B. M. & Butler, J. J. Residual fibrous masses in treated Hodgkin\u2019s disease. Cancer 60, 407\u2013413. https:\/\/doi.org\/10.1002\/1097-0142(19870801)60:3%3c407::aid-cncr2820600321%3e3.0.co;2-n (1987).","journal-title":"Cancer"},{"key":"31941_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3892\/ijo.2020.4955","volume":"56","author":"MS Kalemaki","year":"2020","unstructured":"Kalemaki, M. S. et al. PET\/CT and PET\/MRI in ophthalmic oncology (Review). Int. J. Oncol. 56, 417\u2013429. https:\/\/doi.org\/10.3892\/ijo.2020.4955 (2020).","journal-title":"Int. J. Oncol."},{"key":"31941_CR34","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-14-2454","volume":"21","author":"ME Mayerhoefer","year":"2015","unstructured":"Mayerhoefer, M. E. et al. Evaluation of diffusion-weighted magnetic resonance imaging for follow-up and treatment response assessment of lymphoma: Results of an 18F-FDG-PET\/CT-controlled prospective study in 64 patients. Clin. Cancer Res. 21, 2506\u20132513. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2454 (2015).","journal-title":"Clin. Cancer Res."},{"key":"31941_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/blood.2021013239","volume":"139","author":"ME Mayerhoefer","year":"2022","unstructured":"Mayerhoefer, M. E. et al. CXCR4 PET\/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication. Blood 139, 240\u2013244. https:\/\/doi.org\/10.1182\/blood.2021013239 (2022).","journal-title":"Blood"},{"key":"31941_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/RLU.0000000000001395","volume":"41","author":"ME Mayerhoefer","year":"2016","unstructured":"Mayerhoefer, M. E. et al. Can interim 18F-FDG PET or diffusion-weighted mri predict end-of-treatment outcome in FDG-avid MALT lymphoma after rituximab-based therapy? A preliminary study in 15 patients. Clin. Nucl. Med. 41, 837\u2013843. https:\/\/doi.org\/10.1097\/RLU.0000000000001395 (2016).","journal-title":"Clin. Nucl. Med."},{"key":"31941_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13550-019-0562-1","volume":"9","author":"HL Park","year":"2019","unstructured":"Park, H. L. et al. Role of F-18 FDG PET\/CT in non-conjunctival origin ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphomas. EJNMMI Res. 9, 99. https:\/\/doi.org\/10.1186\/s13550-019-0562-1 (2019).","journal-title":"EJNMMI Res."},{"key":"31941_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31941-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31941-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31941-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T14:11:58Z","timestamp":1679580718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31941-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31941"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31941-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"17 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4792"}}